Clinical application value of soluble co-stimulatory molecule B7-H1 detection in colorectal cancer

Abstract

Objective To determine the level of soluble B7-H1 (sB7-H1) in serum of patients with colorectal cancer (CRC), and to investigate its clinical application value in CRC. Methods 152 cases of CRC, 57 cases of benign colorectal diseases and 59 healthy subjects were enrolled. ELISA was used to determine the sB7-H1 level in serum. The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 72-4 (CA72-4) were determined by electrochemiluminescence. The level of carbohydrate antigen 50 (CA-50) was determined by chemiluminescence. ROC curve was used to evaluate the diagnostic efficiency of sB7-H1 alone or combined with other tumor markers in CRC.It also analyzed the correlation between serum sB7-H1 level and some clinicopathological characteristics including tumor location, depth of invasion, lymph node metastasis status, distant metastasis status and tumor stages. Results (1)The differences of sB7-H1 level among CRC group, colorectal benign disease group and healthy control group (compared with each other respectively) were statistically significant (P 0.05). (2)The diagnosis ability of sB7-H1, CEA, CA19-9, CA72-4, and CA-50 were determined by the area under curve (AUC), which was 0.730, 0.772, 0.639, 0.663 and 0.635, respectively. The combination of sB7-H1 and CEA showed the best effect, and the AUC reached 0.831. (3)There was no significant correlation between the levels of sB7-H1 and CEA, or CA19-9, CA72-4, CA-50. (4)Immunohistochemistry result showed that the positive rate of CRC group was 52%, while that of benign disease group was 6.3%. The difference of the positive rate between two groups was statistically significant (P 0.05). Conclusion Serum sB7-H1 has a high clinical application value and could serve as a new tumor marker in CRC.(Chin J Lab Med, 2018, 41: 669-674) Key words: Colorectal neoplasms; Antigens, CD274; Biomarkers, tumor